II. Define the issue-specific to vulvovaginal disease
Evidence-based practice lags behind in this field, particularly when compared with other disciplines in women's health. The development of interventional clinical trials for vulvovaginal conditions is hampered by the lack of essential information required to inform trial design, including validated outcome measures that can be recommended for a core outcome set. As a result, many published randomised studies are heterogeneous, of poor methodological quality and difficult to combine in metaanalysis, meaning that they cannot be utilised to inform evidence based practice.
Other more "developed" disciplines in women's health such as gynecologic oncology, reproductive endocrinology, and maternal-fetal medicine have evolved productive research directions. Research in these disciplines has been facilitated through subspecialty development, preferential research funding, and a perception of significant societal impact from the respective disease states. In contrast, welldesigned, vulvovaginal clinical trials and observational studies, such as in vulvodynia, lichen sclerosus and mucosal / erosive lichen planus, are relatively small in number. [7] [8] [9] In spite of the research neglect, vulvovaginal disorders fall within the top ten ambulatory visits by women and lead to multiple return visits, development of sexual dysfunction, progression of chronic pain, and a negative impact on overall quality-of-life 10 . Clinically, many vulvovaginal complaints are infrequently raised by patients in discussion with the healthcare provider, based on devastating biopsychosexual implications that results in a 'suffering-in-silence'. 11 
III.

What is a core outcome set (COS) and a domain?
A core outcome set is a minimum set of outcomes for all clinical trials of a particular condition/group of conditions and will enable trials to be compared in meta-analyses. Core outcome sets consist of measures of effectiveness that are relevant to patients, care providers, and all other stakeholders.
 'Outcome domains' are distinct elements of a disease (including consequence of the disease) such as patient defined symptoms, physician defined signs, laboratory assessments including histopathology, duration of effect of treatment and quality-of-life.  Outcome measures are 'instruments' that measure the domains. (Schmitt 2015) There is a lack of consensus with regard to the selection of outcomes for clinical trials. 12 As a result, different outcomes are assessed in different trials on the same population and intervention, important outcomes are missed by many trials, and/or different ways of measuring the same outcome domain are used, causing inconsistencies in reporting and difficulties in comparing and combining the findings in systematic reviews and meta-analyses and eventually using (pooled) trial information for clinical decision making. Consensus-based COS development is key to improvement of observational research and clinical trial methods by facilitating multicenter collaboration, providing reproducible measures of outcomes (i.e. drug testing results, disease status changes, etc.), and strengthening between-study comparisons such as meta-analyses. Formally defined structure such as Delphi panels can provide the essential foundation for the construction of widely accepted core outcome sets. 13 Core outcome sets should address the following points:
 Usually consist of measures of effectiveness or harm  Relevant to patients and care providers  Relevant to those making decisions about health care cost-effectiveness  Need to be valid, reliable, responsive to change  Easy to implement  Core outcomes may be different for clinical trials and routine care  Some core outcomes may be generalizable to a wide spectrum of conditions while other core outcomes may be disease-specific
Core outcome domains may cover: It is important to realise that core outcomes are not necessarily the only outcomes to be included in a trial. Other outcomes in addition to the core outcomes may be included to suit the needs of each particular trial. Core outcomes do not necessarily need to be the primary trial outcomes.
IV. Organization is needed for ongoing independent workgroups
Based on a collective recognition of need, a number of workgroups have begun to address improved outcomes research in vulvovaginal disorders. However, the ongoing initiatives lack a unified focus and integration of efforts. Inevitably, the various workgroups will uncover common ground with respect to sexual dysfunction, chronic pain / itching, emotional disorders such as depression, and quality-of-life experience. Diverse diagnoses such as vulvodynia, lichen sclerosus, erosive lichen planus, recurrent vulvovaginal candidiasis, and vaginal atrophy will be found to be connected, based on blurred diagnostic boundaries or linked disease relationships. There is, therefore, need for a unified, focused, integrated consensus effort.
V. Proposal: Development of a broad-based COS for vulvovaginal disease (VVD)
In spite of the relatively broad range of conditions encountered by specialists in the field, several factors argue for COS development that will span the spectrum of disease affecting the female lower genital tract:
 The diagnostic hallmarks of many vulvovaginal conditions, such as vulvodynia, lichen sclerosus, vaginal atrophy, and recurrent vulvovaginal candidiasis, are unclearly defined and are often coexisting.  Diverse vulvovaginal afflictions promote a common psychosexual impact on the afflicted patient. This encourages a common assessment of patient reported quality-of-life outcomes across a spectrum of disorders.  Developmentally, the three closely juxtaposed embryologic derivatives, making up the female lower genital tract may lead to confusing differences in tissue behavior within an anatomically unified region. 16 A classic example of physiologic variation based upon embryologic origin is seen in the difference in estrogen responsiveness between the vagina and vulvar vestibule.
The primary goal of a vulvovaginal disease COS initiative would be to develop consensus opinion concerning common domains and outcome measure instruments for vulvovaginal disorders. Publication of these consensus opinions would provide well defined, concrete direction for future research in the field.
We propose defining core domains, and identifying vulvovaginal disease COS and outcome assessment instruments that focus on at least three vulvovaginal disease subject areas:
 Vulvar inflammatory Dermatoses  Vulvar Pain States (Vulvodynia)  Vaginitis (Infectious (and non-infectious))
The vulvovaginal disease COS initiative should remain relatively broad in scope of medical conditions, be internationally-based, involve a broad stake holder group, and utilize recognized consensus methods such as Delphi panels and patient-centered focus groups.
VI.
The initial roadmap of COS development Prior expert panel consensus initiatives such as IMMPACT 2 provide a clear roadmap for development of a series of major meetings covering all vulvovaginal COS areas and focused on three goals: 1) Delimiting clinical conditions and identifying core domains within each condition, 2) Identifying and defining core outcomes / instruments, and 3) Development of clinical research structure for randomized clinical trials (RCTs) in the respective subject areas. Core domains, such as sexual dysfunction and pain, would span all vulvovaginal conditions. Additional area-specific domains such as 'dermatologic architectural change' and 'laboratory assessment of vaginal milieu' would also be developed. Publication of internationally accepted core outcome measures for clinical trials and observational studies would enable the synthesis of evidence-based practice by facilitating crosscomparison and meta-analysis of studies.
Further points in COS development:
 Language / cultural issues: The vulvovaginal COS initiative should provide similar patientdirected measures across cultures and languages. Stakeholders must be internationally-based, including public, medical researchers, health care professionals, and health care policy experts with a global perspective. This will require appropriate translation. Cultural response differences will likely be recognized requiring alteration of measurement tools. PROMIS guidelines 1 will provide important direction in this instance.  HPV associated / neoplastic disease: Updated consensus guidelines are in process of development and publication by a dedicated expert panel. HPV associated disease, therefore, will not be covered in this initiative. Future integration of COS for genital neoplasia will likely occur following the updated guideline roll-out. 
